Helmut Butzkueven

Navedeno

	Vse	Od leta 2020
Navedbe	27367	14016
indeks h	74	55
indeks i10	265	217

2900

1450

725

2175

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202581 100 150 197 244 303 485 512 764 1028 1105 1389 1514 1486 1662 1868 2377 2780 2718 2695 2851 553

Javni dostop

Prikaži vse

178 člankov

30 člankov

na voljo

ni na voljo

Na podlagi zahtev v povezavi s financiranjem

Soavtorji

Trevor J KilpatrickProfessor of NeurologyPreverjeni e-poštni naslov na unimelb.edu.au
Anneke Van Der WaltAssociate Professor, Central Clinical School, Monash UniversityPreverjeni e-poštni naslov na monash.edu
Bruce V Taylormenzies Research Institute Tasmania University of TasmaniaPreverjeni e-poštni naslov na utas.edu.au
Jeannette Lechner-ScottHunter Medical Research InstitutePreverjeni e-poštni naslov na health.nsw.gov.au
maria trojanoDipartimento di Scienze Mediche di Base, Neuroscienze ed Organi di Senso, Università degli StudiPreverjeni e-poštni naslov na uniba.it
Associate Professor Vilija G. JokubaitisNeuroimmunology Genomics and Prognostics Group Head, Monash UniversityPreverjeni e-poštni naslov na monash.edu
Tomas KalincikProfessor of Neurology, University of Melbourne and Royal Melbourne HospitalPreverjeni e-poštni naslov na unimelb.edu.au
Jim StankovichStatistician, Primary Health TasmaniaPreverjeni e-poštni naslov na primaryhealthtas.com.au
Michael BarnettThe University of Sydney / Brain and Mind CentrePreverjeni e-poštni naslov na sydney.edu.au
Ludwig KapposUniversity of Basel and Research Center of Clinical Neuroimmunology and Neuroscience Basel (RC2NB)Preverjeni e-poštni naslov na uhbs.ch
Mastura MonifAssociate Professor, Dept of Neurosciences, Monash University), Neurologist (AlfredPreverjeni e-poštni naslov na monash.edu
Scott KolbeMonash UniversityPreverjeni e-poštni naslov na monash.edu
Gary EganMonash Biomedical Imaging, Monash UniversityPreverjeni e-poštni naslov na monash.edu
Heinz WiendlUniversity of MünsterPreverjeni e-poštni naslov na uni-muenster.de
Gavin GiovannoniQueen Mary University of LondonPreverjeni e-poštni naslov na giovannoni.net
Maria Pia SormaniUniversity of GenoaPreverjeni e-poštni naslov na unige.it
Ingrid van der MeiMenzies Institute for Medical Research, University of TasmaniaPreverjeni e-poštni naslov na utas.edu.au
Justin Paul RubioAssociate Prof of Human Genetics, The Florey Institute of Neuroscience andPreverjeni e-poštni naslov na unimelb.edu.au
Peter J MitchellDirector of Neurointervention, The Royal Melbourne HospitalPreverjeni e-poštni naslov na mh.org.au
Terence J. O'BrienThe Department of Neuroscience, Monash University; Department of Neurology, Alfred HealthPreverjeni e-poštni naslov na monash.edu

Spremljaj

Helmut Butzkueven

MSNI Research Group, Dept of Neuroscience, School of Translational Medicine, Monash University

Preverjeni e-poštni naslov na monash.edu

Multiple Sclerosis and Neuroimmunology


Naslov Razvrsti po navedbah Razvrsti po letniku Razvrsti po naslovu	Navedeno Navedeno	Leto
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Nature 476 (7359), 214-219, 2011	3094	2011
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ... Nature genetics 45 (11), 1353-1360, 2013	1407	2013
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ... Neurology 64 (7), 1144-1151, 2005	1124	2005
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018	1080	2018
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, R Simmons, ... Bmj 327 (7410), 316, 2003	772	2003
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability CL Martin, BA Phillips, TJ Kilpatrick, H Butzkueven, N Tubridy, ... Multiple Sclerosis Journal 12 (5), 620-628, 2006	755	2006
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination S Ramanathan, S Mohammad, E Tantsis, TK Nguyen, V Merheb, ... Journal of Neurology, Neurosurgery & Psychiatry 89 (2), 127-137, 2018	573	2018
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019	561	2019
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20 Data analysis: Bahlo Melanie 2 Brown Matthew A 6 7 Browning Brian L 20 ... Nature genetics 41 (7), 824-828, 2009	550	2009
Brain health: time matters in multiple sclerosis G Giovannoni, H Butzkueven, S Dhib-Jalbut, J Hobart, G Kobelt, G Pepper, ... Multiple sclerosis and related disorders 9, S5-S48, 2016	544	2016
Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016	460	2016
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, BV Taylor, T Kilpatrick, ... Journal of neurology 254, 581-590, 2007	441	2007
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ... The Lancet Neurology 19 (4), 307-316, 2020	378	2020
Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci NA Patsopoulos, ... Annals of neurology 70 (6), 897-912, 2011	370	2011
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival H Butzkueven, JG Zhang, M Soilu-Hanninen, H Hochrein, F Chionh, ... Nature medicine 8 (6), 613-619, 2002	338	2002
Geographical variations in sex ratio trends over time in multiple sclerosis M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ... PloS one 7 (10), e48078, 2012	278	2012
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, L Vanopdenbosch, ... The Lancet Neurology 16 (3), 189-199, 2017	277	2017
Onset seizures independently predict poor outcome after subarachnoid hemorrhage H Butzkueven, AH Evans, A Pitman, C Leopold, DJ Jolley, AH Kaye, ... Neurology 55 (9), 1315-1320, 2000	262	2000
Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis S Simpson-Yap, E De Brouwer, T Kalincik, N Rijke, JA Hillert, C Walton, ... Neurology 97 (19), e1870-e1885, 2021	250	2021
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis MS Stein, Y Liu, OM Gray, JE Baker, SC Kolbe, MR Ditchfield, GF Egan, ... Neurology 77 (17), 1611-1618, 2011	247	2011

Sistem trenutno ne more izvesti postopka. Poskusite znova pozneje.

Članki 1–20

Št. navedb na leto

Podvojene navedbe

Združene navedbe

Dodajanje soavtorjevSoavtorji

Spremljaj

Navedeno

Soavtorji